Insulin

Insulin is a peptide hormone produced by the beta cells of the pancreas. Its fundamental role is to lower blood glucose by helping cells take up and store sugar from the bloodstream. It is one of the most important hormones in human metabolism and one of the most consequential medicines ever developed.

For people with diabetes, prescription insulin is life-saving. At the same time, insulin is a hormone with an extremely narrow margin for error: too much can cause severe, rapid, and potentially fatal hypoglycemia. Any interest in insulin outside of supervised medical treatment for diabetes is dangerous, and this page is strongly safety-forward for that reason.

Insulin binds the insulin receptor on cells throughout the body and triggers signaling that moves glucose out of the blood and into tissues. High-level themes include:

• Prompting muscle and fat cells to take up glucose from the bloodstream

• Signaling the liver to store glucose and reduce its own glucose output

• Influencing the storage of fat and the building blocks used by cells

Because insulin so effectively lowers blood glucose, the central danger is hypoglycemia: driving blood sugar too low, which can rapidly impair the brain and become an emergency.

In approved clinical use, insulin is prescribed to manage diabetes, essential for type 1 diabetes and used in many people with type 2 diabetes. It is dosed and adjusted by clinicians in relation to food, activity, and glucose monitoring.

Outside of supervised diabetes care, insulin has sometimes been misused in bodybuilding and performance contexts. This non-medical use is exceptionally hazardous because it deliberately manipulates a hormone whose overshoot can be fatal within a short time. The distinction between careful medical management and self-directed use could not be sharper.

Insulins occupy their own numbered entry, S4.4.2, within the Metabolic Modulators section of the WADA Prohibited List — sitting between AMPK activators and PPARδ agonists (S4.4.1), meldonium (S4.4.3) and trimetazidine (S4.4.4). The entry covers insulin-mimetics as well, so non-insulin molecules that reproduce insulin signalling are captured. S4.4 substances are non-Specified, which means the default sanction for a first violation is four years and there is no reduced tier for arguing the use was not performance-motivated.

The TUE is the entire story for this substance. Insulin is the clearest case on the list where prohibition and legitimate necessity collide: an athlete with type 1 diabetes cannot compete without it. A Therapeutic Use Exemption granted against documented diagnosis resolves that, and the requirement is prospective — the exemption has to be in place, not argued for after an adverse analytical finding. Athletes with insulin-treated diabetes are among the most routine TUE holders in the system.

Outside that route, insulin is misused in strength and physique disciplines for its anabolic and nutrient-partitioning effects, typically stacked with growth hormone. It is among the most dangerous drugs in that context because the margin between an anabolic dose and a hypoglycaemic emergency is narrow, the effect is not dose-titratable by feel, and severe hypoglycaemia causes neurological injury or death within hours. The anti-doping prohibition and the clinical risk point the same direction here, which is not true of every entry on the list.

Even in carefully managed diabetes care, hypoglycemia is a recognized hazard, which is why treatment involves glucose monitoring, education, and a plan for treating lows. Other considerations in clinical use can include injection-site reactions and weight changes.

In unsupervised, non-medical use, none of these safeguards exist, and the consequences of a miscalculation can be immediate and irreversible. This is a substance where safety is the central story, and no high-level summary can substitute for clinical care.

Conceptually, insulin products differ in how quickly they act and how long their effect lasts, which is why diabetes care matches formulations to a person's needs and monitoring. Any legitimate use is a clinical decision guided by glucose data.

The key idea for a general reader is that insulin's power to lower glucose is exactly what makes precise, monitored dosing essential and self-direction dangerous.

Insulin is not one product. Marketed insulins are grouped by how fast they act and how long the effect lasts, and diabetes care works by combining them:

• Rapid-acting analogues — insulin lispro (Humalog), insulin aspart, insulin glulisine. Engineered to be absorbed faster and clear sooner than regular human insulin, so they can be taken close to a meal.

• Human insulins — regular (Humulin R, Novolin R) and NPH (Humulin N, Novolin N), plus fixed premixes such as 70/30. These are the original recombinant products and remain widely used.

• Long-acting analogues — insulin glargine (Lantus), insulin detemir (Levemir), insulin degludec (Tresiba), designed to provide a flat background level rather than a mealtime peak.

• Non-injected forms — inhaled insulin human (Afrezza) is an approved metered powder, and subcutaneous pumps deliver rapid-acting insulin continuously.

Concentration is a separate axis from duration and a recognised source of medication error: Humalog is sold as both U-100 and U-200 (100 and 200 units per mL), and pens differ in whether they dial in 1-unit or 0.5-unit increments (Humalog prescribing information). The same label carries a standing instruction never to share a pen, cartridge, or syringe between people even if the needle is changed, because of blood-borne pathogen transmission.

Since March 2020 insulins have been regulated in the US as biological products rather than as drugs, which opened the pathway for biosimilar and interchangeable insulins (FDA, February 2020). That is a supply-and-pricing story, not a change in how the hormone behaves.

Insulin has one of the deepest evidence bases in all of medicine. Since its discovery, research transformed type 1 diabetes from a fatal condition into a manageable one and continues to refine formulations, delivery, and monitoring for safer, more physiological glucose control.

That same research consistently underscores hypoglycemia as the defining risk and the reason insulin therapy is built around monitoring and individualization. Any claim that frames non-medical insulin use as a safe way to alter body composition or performance is not supported by the evidence and ignores a well-documented, potentially fatal hazard.

For deeper dives on this substance, see:

• Insulin benefits and areas of interest
• Insulin side effects and safety context
• Insulin dosing concepts (educational)
• Insulin research and evidence overview

Is insulin a peptide or a protein? Both labels are defensible, and insulin is usually called a peptide hormone. The mature molecule is 51 amino acids in two chains — a 21-residue A chain and a 30-residue B chain — held together by two disulfide bridges, with a third bridge inside the A chain. It is cut out of a 110-residue precursor, preproinsulin, with the connecting C-peptide removed during processing (UniProt P01308). At 51 residues it sits right at the fuzzy boundary where "long peptide" becomes "small protein."

Why is insulin on a peptide reference site at all? Because it is the reference case. Insulin is the peptide hormone every other entry on this site gets compared against: it has a defined receptor, a defined sequence, a recombinant manufacturing route, and decades of trial data. It is also the compound most often stacked alongside growth hormone in physique misuse, which is why it turns up in the same searches as research peptides despite being a prescription medicine.

Why is non-medical insulin use so dangerous? Because the failure mode is fast and irreversible. Hypoglycemia is the most common adverse reaction of every insulin product, and severe hypoglycemia can cause seizures, may be life-threatening, or cause death (Humalog prescribing information). In supervised diabetes care that risk is managed with glucose monitoring, dose titration, and a rehearsed plan for treating lows. Self-directed use has none of those, and the practice has been described in the medical literature specifically as a hazard — a 2003 case report in the British Journal of Sports Medicine was published to highlight the dangers of insulin abuse in body building (Evans & Lynch 2003), following an earlier report of the practice in JAMA (Rich et al. 1998).

Does insulin build muscle? Not the way the marketing implies. When forearm muscle kinetics were measured directly during insulin infusion in seven healthy men, net protein balance turned positive — but protein synthesis did not change at all. The entire effect came from suppressing protein breakdown (Gelfand & Barrett, J Clin Invest 1987). Insulin is anti-catabolic in human muscle rather than anabolic in the way a growth factor is, and no trial has established that non-medical insulin produces a safe body-composition benefit.

Is insulin banned in sport? Yes, at all times, in and out of competition. Insulins have their own numbered entry — S4.4.2, "insulins and insulin-mimetics" — in the Metabolic Modulators section of the WADA Prohibited List. It is a non-Specified Substance, so the default first sanction is four years. An athlete with insulin-treated diabetes competes under a prospectively granted Therapeutic Use Exemption, which is one of the most routine TUEs in the system.

Why is insulin regulated as a biologic rather than as a drug? It was reclassified. On 23 March 2020, insulin applications approved under the Food, Drug, and Cosmetic Act were deemed licences under the Public Health Service Act, which for the first time allowed manufacturers to file products as biosimilar to — or interchangeable with — an existing insulin (FDA announcement, February 2020). This changed the competition and pricing pathway, not the pharmacology.

What actually differs between a rapid-acting analogue and regular human insulin? Timing, not strength. One unit of insulin lispro has the same glucose-lowering effect as one unit of regular human insulin on a molar basis; what the amino-acid substitutions change is that lispro has a faster onset and a shorter duration when injected subcutaneously (Humalog prescribing information). The label also cautions that onset, peak, and duration vary considerably between people and even within the same person, which is a large part of why insulin cannot be dosed by feel.